Irvine Scientific introduces BalanCD HEK293 system for large-scale expression of proteins and viral vectors
New product range includes chemically-defined, serum-free media, to increase productivity of viral vectors and recombinant proteins in suspension cultures.
Irvine Scientific has introduced their BalanCD HEK293 System. The system includes a highly versatile series of chemically-defined media designed to increase productivity in a range of applications, rapidly delivering high yields of viral vectors and recombinant proteins.
BalanCD HEK293 System is fully scalable, and supports small to industrial scale batch sizes. Utilizing human embryonic kidney (HEK293) cells, the system supports applications including viral vector production for gene therapy, transient gene expression and recombinant protein production in suspension-adapted HEK293 cells.
Central to the new system’s versatility, scalability, and process efficiency is BalanCD HEK293, a bi-functional medium that supports both growth and transfection in multiple 293 cell lines, which means that there is no need to change media before and after transfection. This is complemented by BalanCD HEK293 Feed, designed to support high density cell growth to maximize production of recombinant proteins. Anti-Clumping Supplement further increases productivity by preventing the natural tendency of HEK293 to aggregate, thereby improving growth.
“Gene therapy is at the forefront of new medical therapies, but the ability to reliably produce viral vectors at industrial scale has been a challenge,” explained Dr Jessie Ni, Chief Scientific Officer at Irvine Scientific. “Our goal is to provide a reproducible solution to attaining high yields of viral vectors using a chemically-defined, suspension-cell-based platform that will help scientists further their ability to provide innovative treatments. Additionally, we designed the BalanCD HEK293 System to provide unmatched flexibility as well as performance to scientists working with 293 cell lines for other applications such as transient protein expression.”
To save time and cost in downstream processing, and to help meet regulatory requirements, BalanCD HEK293 growth and feed media are chemically-defined and animal component-free. Anti-Clumping Supplement is animal-component-free and enzyme-free. All products are manufactured in state-of-the-art cGMP facilities using strict raw material controls. To further facilitate regulatory compliance, Drug Master Files have been filed with the FDA.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.